151 related articles for article (PubMed ID: 21276442)
1. Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31®.
Cheng C; Cruz-Fisher MI; Tifrea D; Pal S; Wizel B; de la Maza LM
Vaccine; 2011 Mar; 29(13):2437-43. PubMed ID: 21276442
[TBL] [Abstract][Full Text] [Related]
2. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.
Sun G; Pal S; Weiland J; Peterson EM; de la Maza LM
Vaccine; 2009 Aug; 27(36):5020-5. PubMed ID: 19446590
[TBL] [Abstract][Full Text] [Related]
3. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin.
Cheng C; Bettahi I; Cruz-Fisher MI; Pal S; Jain P; Jia Z; Holmgren J; Harandi AM; de la Maza LM
Vaccine; 2009 Oct; 27(44):6239-46. PubMed ID: 19686693
[TBL] [Abstract][Full Text] [Related]
4. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge.
Pal S; Davis HL; Peterson EM; de la Maza LM
Infect Immun; 2002 Sep; 70(9):4812-7. PubMed ID: 12183524
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.
Tifrea DF; Pal S; Toussi DN; Massari P; de la Maza LM
Microbes Infect; 2013 Nov; 15(13):920-7. PubMed ID: 23999313
[TBL] [Abstract][Full Text] [Related]
6. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
[TBL] [Abstract][Full Text] [Related]
7. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.
Cheng C; Jain P; Bettahi I; Pal S; Tifrea D; de la Maza LM
Vaccine; 2011 Sep; 29(38):6641-9. PubMed ID: 21742006
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.
Ralli-Jain P; Tifrea D; Cheng C; Pal S; de la Maza LM
Vaccine; 2010 Nov; 28(48):7659-66. PubMed ID: 20875490
[TBL] [Abstract][Full Text] [Related]
9. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model.
Cheng C; Pal S; Bettahi I; Oxford KL; Barry PA; de la Maza LM
Vaccine; 2011 Apr; 29(18):3456-64. PubMed ID: 21376796
[TBL] [Abstract][Full Text] [Related]
11. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge.
Pal S; Luke CJ; Barbour AG; Peterson EM; de la Maza LM
Vaccine; 2003 Mar; 21(13-14):1455-65. PubMed ID: 12615442
[TBL] [Abstract][Full Text] [Related]
12. Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.
Tifrea DF; Pal S; Popot JL; Cocco MJ; de la Maza LM
J Immunol; 2014 Jun; 192(11):5201-13. PubMed ID: 24778450
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of amphipol-conjugated adjuvant with antigen, and adjuvant combinations, enhance immune protection elicited by a membrane protein-based vaccine against a mucosal challenge with Chlamydia.
Tifrea DF; Pal S; Le Bon C; Giusti F; Popot JL; Cocco MJ; Zoonens M; de la Maza LM
Vaccine; 2018 Oct; 36(45):6640-6649. PubMed ID: 30293763
[TBL] [Abstract][Full Text] [Related]
14. Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine.
Tifrea DF; Sun G; Pal S; Zardeneta G; Cocco MJ; Popot JL; de la Maza LM
Vaccine; 2011 Jun; 29(28):4623-31. PubMed ID: 21550371
[TBL] [Abstract][Full Text] [Related]
15. Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant.
Tifrea DF; Pal S; le Bon C; Cocco MJ; Zoonens M; de la Maza LM
Vaccine; 2020 Jun; 38(28):4412-4422. PubMed ID: 32386746
[TBL] [Abstract][Full Text] [Related]
16. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge.
Pal S; Theodor I; Peterson EM; de la Maza LM
Infect Immun; 1997 Aug; 65(8):3361-9. PubMed ID: 9234798
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.
Tifrea DF; Ralli-Jain P; Pal S; de la Maza LM
Infect Immun; 2013 May; 81(5):1741-50. PubMed ID: 23478318
[TBL] [Abstract][Full Text] [Related]
18. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection.
Su H; Parnell M; Caldwell HD
Vaccine; 1995 Aug; 13(11):1023-32. PubMed ID: 8525685
[TBL] [Abstract][Full Text] [Related]
19. Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection.
Hickey DK; Aldwell FE; Beagley KW
Vaccine; 2010 Feb; 28(7):1668-72. PubMed ID: 20026449
[TBL] [Abstract][Full Text] [Related]
20. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
Hickey DK; Aldwell FE; Beagley KW
Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
